poisar

Stocks · News reference

CG Oncology Announces Positive Topline Results from Phase 3 PIVOT-006 Trial

Fiscal.ai

CG Oncology reported positive topline results from its Phase 3 PIVOT-006 trial evaluating cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta bladder cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — CG Oncology, Inc. (CGON)

    Filed: 2026-11-16 AccNo: 0001193125-26-462199 Size: 17 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits